LORTAB 2.5/500

Compare LORTAB 2.5/500  to:
Compare
Compare

Generic Name for LORTAB 2.5/500

Hydrocodone bitartrate 2.5mg, acetaminophen 500mg; scored tabs.

Legal Classification:

CIII

Pharmacological Class for LORTAB 2.5/500

Opioid + analgesic.

Manufacturer of LORTAB 2.5/500

UCB Inc.

Indications for LORTAB 2.5/500

Moderate to moderately severe pain.

Adult dose for LORTAB 2.5/500

2.5/500 or 5/500: 1–2 tabs every 4–6 hrs as needed; max 8 tabs/day.

Children's dosing for LORTAB 2.5/500

Use Elixir.

Also:

Precautions for LORTAB 2.5/500

Head injury. Increased intracranial pressure. Acute abdomen. Impaired renal, hepatic, thyroid, pulmonary, or adrenocortical function. GI or GU obstruction. Asthma. Drug abusers. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for LORTAB 2.5/500

Potentiation with alcohol, CNS depressants, MAOIs, tricyclic antidepressants, anticholinergics.

Adverse Reactions for LORTAB 2.5/500

Dizziness, CNS depression, respiratory depression, GI upset, constipation, urinary retention; hepatotoxicity (overdosage).

How is LORTAB 2.5/500 supplied?

Tabs 2.5/500—100
5/500, 7.5/500, 10/500—100, 500
Elixir—pt

Related Disease:

Pain, general~narcotics

Related Resources

Exalgo approved for moderate to severe pain

March 02, 2010

The FDA has approved Exalgo (hydromorphone HCl extended-release tablets, from Covidien) for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

Phase 3 study of MoxDuo IR for pain management

February 10, 2010

QRxPharma Limited announced initiation of a second Phase 3 registration trial (Study 009) to evaluate its MoxDuo IR (morphine and oxycodone) product for the management of moderate to severe pain in patients who have undergone total knee replacement surgery.

FDA-approved morphine sulfate oral solution 100mg/5mL available

January 27, 2010

Roxane Laboratories announced that the New Drug Application (NDA) for high concentrate morphine sulfate oral solution 100mg/5mL (20mg/mL) has been approved by the FDA.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

NDA submitted for extended-release tapentadol tablets for chronic pain

December 02, 2009

Johnson & Johnson and its subsidiaries, PriCara and Ortho-McNeil-Janssen, announced that they have submitted a New Drug Application (NDA) to the FDA for tapentadol extended release (ER) tablets for the management of moderate to severe chronic pain in patients ≥18 years of age.